We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.
- Authors
Ringe, J D; Dorst, A; Faber, H; Ibach, K; Preuss, J
- Abstract
Corticosteroids are widely prescribed, although treatment-related side-effects are common. Of these adverse events (AEs), osteoporosis is considered the most serious. Currently, oral bisphosphonates are the standard treatment for corticosteroid-induced osteoporosis (CIO). However, intermittent intravenous (i.v.) therapy may have advantages, including lack of gastrointestinal AEs, improved bioavailability and increased compliance. This study investigated the efficacy and safety of 3-monthly i.v. ibandronate bolus injections in patients with established CIO. The results from a planned 2-yr interim analysis are reported.
- Publication
Rheumatology (Oxford, England), 2003, Vol 42, Issue 6, p743
- ISSN
1462-0324
- Publication type
Journal Article
- DOI
10.1093/rheumatology/keg205